论文部分内容阅读
[目的]观察贝伐单抗治疗转移性结直肠癌中高血压的发生情况,评价其对贝伐单抗疗效的预测价值。[方法]回顾性分析贝伐单抗联合化疗治疗的转移性结直肠癌患者中,不良反应高血压的发生情况。根据是否发生贝伐单抗相关性高血压把患者分为两组,比较两组疾病有效率(RR)情况。[结果]64例患者中完全缓解(CR)5例(7.8%),部分缓解(PR)31例(48.4%)。使用贝伐单抗出现高血压的患者为15例,CR+PR为12例,RR为80.0%,而使用贝伐单抗未出现高血压的患者为49例,其中CR+PR为24例,RR为49.0%。两组比较差异无统计学意义(P=0.034).[结论]高血压为贝伐单抗治疗转移性结直肠癌中常见不良反应,高血压的出现有可能成为判断其疗效的较好的预测因子。
[Objective] To observe the incidence of hypertension in bevacizumab-treated metastatic colorectal cancer and evaluate its predictive value for the efficacy of bevacizumab. [Methods] The incidence of adverse reactions in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy was retrospectively analyzed. The patients were divided into two groups according to whether bevacizumab-related hypertension occurred or not, and the disease efficiency (RR) was compared between the two groups. [Results] Among the 64 patients, complete remission (CR) occurred in 5 (7.8%) and partial remission (PR) in 31 patients (48.4%). Among the 15 patients who developed high blood pressure with bevacizumab, CR + PR was 12 and RR was 80.0%, compared with 49 without bevacizumab (CR + PR, 24) RR was 49.0%. There was no significant difference between the two groups (P = 0.034). [Conclusion] Hypertension is a common adverse reaction of bevacizumab in the treatment of metastatic colorectal cancer, and the occurrence of hypertension may be a better predictor of the curative effect factor.